

Manuel Luque-Ramírez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5268526/publications.pdf>

Version: 2024-02-01

115
papers

4,296
citations

126907

33
h-index

118850

62
g-index

124
all docs

124
docs citations

124
times ranked

4696
citing authors

#	ARTICLE	IF	CITATIONS
1	High serum copeptin may be a marker of an increased carotid intima-media thickness in asymptomatic patients with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108085.	2.3	0
2	Impact of excluding hyperglycemia from international diabetes federation metabolic syndrome diagnostic criteria on prevalence of the syndrome and its association with microvascular complications, in adult patients with type 1 diabetes. <i>Endocrine</i> , 2022, 76, 601-611.	2.3	2
3	Prevalence of PCOS and related hyperandrogenic traits in premenopausal women with type 1 diabetes: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2022, 28, 501-517.	10.8	13
4	Point-of-care sural nerve conduction could predict the presence of cardiovascular autonomic neuropathy in type 1 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1347-1356.	2.4	2
5	Effect of Iron Depletion by Bloodletting vs. Observation on Oxidative Stress Biomarkers of Women with Functional Hyperandrogenism Taking a Combined Oral Contraceptive: A Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3864.	2.4	2
6	Fasting serum copeptin and asymptomatic peripheral artery disease: No association in patients with type 1 diabetes mellitus. <i>Diabetes and Metabolism</i> , 2021, 47, 101207.	2.9	3
7	Acute-phase glycoprotein profile responses to different oral macronutrient challenges: Influence of sex, functional hyperandrogenism and obesity. <i>Clinical Nutrition</i> , 2021, 40, 1241-1246.	5.0	11
8	Iron Overload in Functional Hyperandrogenism: In a Randomized Trial, Bloodletting Does Not Improve Metabolic Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1559-e1573.	3.6	6
9	Postprandial responses of circulating energy homeostasis mediators to single macronutrient challenges: influence of obesity and sex hormones. <i>Food and Function</i> , 2021, 12, 1051-1062.	4.6	5
10	Type 1 diabetes mellitus and polycystic ovary syndrome. <i>Nature Reviews Endocrinology</i> , 2021, 17, 701-702.	9.6	5
11	Bloodletting has no effect on the blood pressure abnormalities of hyperandrogenic women taking oral contraceptives in a randomized clinical trial. <i>Scientific Reports</i> , 2021, 11, 22097.	3.3	0
12	Postprandial inflammatory responses after oral glucose, lipid and protein challenges: Influence of obesity, sex and polycystic ovary syndrome. <i>Clinical Nutrition</i> , 2020, 39, 876-885.	5.0	20
13	Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 208-215.	4.4	7
14	Apparent mineralocorticoid excess as a side effect of ketoconazole therapy in a patient with Cushing's disease. <i>Clinical Endocrinology</i> , 2020, 92, 80-83.	2.4	2
15	A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1559-1576.	2.4	3
16	2D Diffusion-Ordered ¹ H-NMR Spectroscopy Lipidomic Profiling after Oral Single Macronutrient Loads: Influence of Obesity, Sex, and Female Androgen Excess. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1900928.	3.3	7
17	TLR2 and TLR4 Surface and Gene Expression in White Blood Cells after Fasting and Oral Glucose, Lipid and Protein Challenges: Influence of Obesity and Sex Hormones. <i>Biomolecules</i> , 2020, 10, 111.	4.0	19
18	Metabolic Cytokines at Fasting and During Macronutrient Challenges: Influence of Obesity, Female Androgen Excess and Sex. <i>Nutrients</i> , 2019, 11, 2566.	4.1	20

#	ARTICLE	IF	CITATIONS
19	Glycoprotein A and B Height-to-Width Ratios as Obesity-Independent Novel Biomarkers of Low-Grade Chronic Inflammation in Women with Polycystic Ovary Syndrome (PCOS). <i>Journal of Proteome Research</i> , 2019, 18, 4038-4045.	3.7	36
20	Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test?. <i>Metabolism: Clinical and Experimental</i> , 2019, 93, 86-92.	3.4	18
21	Association of Cardiovascular Autonomic Dysfunction With Peripheral Arterial Stiffness in Patients With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2675-2684.	3.6	12
22	Systemic endocrinopathies (thyroid conditions and diabetes): impact on postnatal life of the offspring. <i>Fertility and Sterility</i> , 2019, 111, 1076-1091.	1.0	7
23	Polycystic ovary syndrome in adult women. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 450-457.	0.2	12
24	Sexual Dimorphism and Sex Steroids Influence Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, e175-e178.	8.6	1
25	Síndrome de ovario poliquístico en la mujer adulta. <i>Medicina Clínica</i> , 2019, 152, 450-457.	0.6	22
26	The peripheral atherosclerotic profile in patients with type 1 diabetes warrants a thorough vascular assessment of asymptomatic patients. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3088.	4.0	15
27	Circulating soluble klotho is not associated with an elevated ankle-brachial index as a surrogate marker of early arterial calcification in patients with type 1 diabetes mellitus and no evidence of renal dysfunction. <i>Diabetes and Metabolism</i> , 2019, 45, 589-592.	2.9	5
28	Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. <i>Metabolism: Clinical and Experimental</i> , 2018, 86, 49-60.	3.4	63
29	Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2018, 24, 225-241.	10.8	36
30	Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1915-1926.	1.8	8
31	Certified testosterone immunoassays for hyperandrogenaemia. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13029.	3.4	5
32	An unusual circulating steroid profile in a virilized postmenopausal woman. <i>Diagnosis</i> , 2018, 5, 83-87.	1.9	4
33	Virilization of a postmenopausal woman by a mucinous cystoadenoma. <i>Oxford Medical Case Reports</i> , 2018, 2018, omx084.	0.4	3
34	Role of sampling times and serum cortisol cut-off concentrations on the routine assessment of adrenal function using the standard cosyntropin test in an academic hospital from Spain: a retrospective chart review. <i>BMJ Open</i> , 2018, 8, e019273.	1.9	11
35	Frequent and Rare HBP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population. <i>Hormone Research in Paediatrics</i> , 2018, 89, 397-407.	1.8	3
36	Impacto de la cesación tabáquica en el riesgo cardiovascular estimado de pacientes con diabetes mellitus tipo 2: El estudio DIABETES. <i>Revista Clínica Española</i> , 2018, 218, 391-398.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Effects of glucose ingestion on circulating inflammatory mediators: Influence of sex and weight excess. <i>Clinical Nutrition</i> , 2017, 36, 522-529.	5.0	14
38	Prevalence of "obesity-associated gonadal dysfunction"™ in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2017, 23, 390-408.	10.8	166
39	Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. <i>European Journal of Endocrinology</i> , 2017, 177, 399-408.	3.7	23
40	Plasma thiobarbituric acid reactive substances (TBARS) in young adults: Obesity increases fasting levels only in men whereas glucose ingestion, and not protein or lipid intake, increases postprandial concentrations regardless of sex and obesity. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1700425.	3.3	22
41	SP551 PARICALCITOL INFLUENCE ON HAEMOGLOBIN LEVELS SHOWING A SYNERGISTIC EFFECT WITH ERYTHROPOIESIS STIMULATING AGENTS AND IRON THERAPY IN HAEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i275-i276.	0.7	0
42	SP557 PARICALCITOL IS ASSOCIATED WITH AN INCREASED PLASMA ERYTHROPOIETIN LEVELS IN ANAEMIC HAEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i277-i278.	0.7	0
43	MP577 DIFFERENCES BETWEEN CALCIFEDIOL AND PARICALCITOL ON SOLUBLE KLOTRO LEVELS IN HAEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i533-i533.	0.7	0
44	Prevalence of male secondary hypogonadism in moderate to severe obesity and its relationship with insulin resistance and excess body weight. <i>Andrology</i> , 2016, 4, 62-67.	3.5	71
45	Differences in analytical and biological results between older and newer lots of a widely used irisin immunoassay question the validity of previous studies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e199-e201.	2.3	14
46	Association of TLR2 S450S and ICAM1 K469E polymorphisms with polycystic ovary syndrome (PCOS) and obesity. <i>Journal of Reproductive Immunology</i> , 2016, 113, 9-15.	1.9	13
47	Adrenal Hyperandrogenism and Polycystic Ovary Syndrome. <i>Current Pharmaceutical Design</i> , 2016, 22, 5588-5602.	1.9	25
48	Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2015, 103, 795-801.e2.	1.0	33
49	FP400 INFLUENCE OF THE SECONDARY HYPERPARATHYROIDISM IN IRON REQUIREMENTS IN DIALYSIS PATIENTS ON ERYTHROPOIESIS-STIMULATING AGENT THERAPY. A PROSPECTIVE CONTROLLED STUDY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii203-iii203.	0.7	0
50	Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, 603-610.	3.7	26
51	Targets to treat androgen excess in polycystic ovary syndrome. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1545-1560.	3.4	15
52	Surrogate Markers of Visceral Adiposity in Young Adults: Waist Circumference and Body Mass Index Are More Accurate than Waist Hip Ratio, Model of Adipose Distribution and Visceral Adiposity Index. <i>PLoS ONE</i> , 2014, 9, e114112.	2.5	86
53	Nonfunctional Metastatic Parathyroid Carcinoma in the Setting of Multiple Endocrine Neoplasia Type 2A Syndrome. <i>Surgery Research and Practice</i> , 2014, 2014, 1-4.	0.5	11
54	Polycystic Ovary Syndrome as a Paradigm for Prehypertension, Prediabetes, and Preobesity. <i>Current Hypertension Reports</i> , 2014, 16, 500.	3.5	31

#	ARTICLE	IF	CITATIONS
55	The striking similarities in the metabolic associations of female androgen excess and male androgen deficiency. <i>Human Reproduction</i> , 2014, 29, 2083-2091.	0.9	79
56	Proteomic analysis of adipose tissue: informing diabetes research. <i>Expert Review of Proteomics</i> , 2014, 11, 491-502.	3.0	9
57	Office Blood Pressure, Ambulatory Blood Pressure Monitoring, and Echocardiographic Abnormalities in Women With Polycystic Ovary Syndrome. <i>Hypertension</i> , 2014, 63, 624-629.	2.7	24
58	Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). <i>Pituitary</i> , 2013, 16, 115-121.	2.9	60
59	Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2013, 19, 268-288.	10.8	399
60	Rare adverse effect of discontinuation of levothyroxine treatment for 131I ablation of thyroid remnant in a patient with differentiated thyroid cancer. <i>Endocrinología Y Nutrición (English Edition)</i> , 2013, 60, 412-414.	0.5	0
61	Evidence for Masculinization of Adipokine Gene Expression in Visceral and Subcutaneous Adipose Tissue of Obese Women With Polycystic Ovary Syndrome (PCOS). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E388-E396.	3.6	63
62	Global Adiposity and Thickness of Intraabdominal and Mesenteric Adipose Tissue Depots Are Increased in Women With Polycystic Ovary Syndrome (PCOS). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1254-1263.	3.6	103
63	Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. <i>Human Reproduction</i> , 2013, 28, 1908-1918.	0.9	60
64	Metabolic Heterogeneity in Polycystic Ovary Syndrome Is Determined by Obesity: Plasma Metabolomic Approach Using GC-MS. <i>Clinical Chemistry</i> , 2012, 58, 999-1009.	3.2	94
65	Cost of Clinical Management of Acromegaly in Spain. <i>Clinical Drug Investigation</i> , 2012, 32, 235-245.	2.2	25
66	Hipercortisolismo de origen suprarrenal: síndrome de Cushing. <i>Medicine</i> , 2012, 11, 861-870.	0.0	0
67	Hiperaldosteronismo primario y secundario. <i>Medicine</i> , 2012, 11, 871-882.	0.0	2
68	Hiperandrogenismo y síndrome de ovario poliquístico. <i>Medicine</i> , 2012, 11, 895-903.	0.0	0
69	Diet composition and physical activity in overweight and obese premenopausal women with or without polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2011, 27, 978-981.	1.7	31
70	Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery. <i>Endocrinología Y Nutrición (English Edition)</i> , 2011, 58, 24-31.	0.5	6
71	The OASIS study: Therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies. <i>Endocrinología Y Nutrición (English Edition)</i> , 2011, 58, 478-486.	0.5	9
72	Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. <i>Fertility and Sterility</i> , 2011, 95, 1048-1058.e2.	1.0	396

#	ARTICLE	IF	CITATIONS
73	Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2011, 95, 1730-1735.e1.	1.0	13
74	Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E251-E259.	3.6	53
75	Role of Decreased Circulating Hepcidin Concentrations in the Iron Excess of Women with the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 846-852.	3.6	81
76	Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study. <i>Endocrinology</i> , 2010, 151, 5974-5974.	2.8	0
77	Obesity impairs general health-related quality of life (HR-QoL) in premenopausal women to a greater extent than polycystic ovary syndrome (PCOS). <i>Clinical Endocrinology</i> , 2010, 73, 595-601.	2.4	19
78	Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study. <i>Endocrine Reviews</i> , 2010, 31, 946-946.	20.1	0
79	The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 222-229.	3.6	56
80	Treatment of Polycystic Ovary Syndrome (PCOS) with Metformin Ameliorates Insulin Resistance in Parallel with the Decrease of Serum Interleukin-6 Concentrations. <i>Hormone and Metabolic Research</i> , 2010, 42, 815-820.	1.5	34
81	The Efficacy of Octreotide LAR as Firstline Therapy for Patients with Newly Diagnosed Acromegaly is Independent of Tumor Extension: Predictive Factors of Tumor and Biochemical Response. <i>Hormone and Metabolic Research</i> , 2010, 42, 38-44.	1.5	13
82	Pegvisomant-Induced Liver Injury Is Related to the UGT1A1*28 Polymorphism of Gilbert's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2147-2154.	3.6	45
83	Recurrent hyponatremia as the presenting feature of a pituitary abscess: A case report. <i>Endocrinología Y Nutrición: Organo De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2010, 57, 123-125.	0.8	6
84	The determinants of insulin sensitivity, β -cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism. <i>Fertility and Sterility</i> , 2010, 94, 2214-2221.	1.0	32
85	Role of Haptoglobin in Polycystic Ovary Syndrome (PCOS), Obesity and Disorders of Glucose Tolerance in Premenopausal Women. <i>PLoS ONE</i> , 2009, 4, e5606.	2.5	31
86	Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. <i>European Journal of Endocrinology</i> , 2009, 160, 535-542.	3.7	53
87	Serum Visceral Adipose Tissue-Derived Serine Protease Inhibitor Concentrations in Human Obesity and Polycystic Ovary Syndrome. <i>Diabetes Care</i> , 2009, 32, e6-e6.	8.6	18
88	Body Iron Stores and Glucose Intolerance in Premenopausal Women. <i>Diabetes Care</i> , 2009, 32, 1525-1530.	8.6	57
89	Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. <i>European Journal of Endocrinology</i> , 2009, 160, 469-480.	3.7	50
90	Antiandrogenic Contraceptives Increase Serum Adiponectin in Obese Polycystic Ovary Syndrome Patients. <i>Obesity</i> , 2009, 17, 3-9.	3.0	33

#	ARTICLE	IF	CITATIONS
91	Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2009, 91, 2527-2536.	1.0	36
92	The Increase in Serum Visfatin After Bariatric Surgery in Morbidly Obese Women is Modulated by Weight Loss, Waist Circumference, and Presence or Absence of Diabetes Before Surgery. <i>Obesity Surgery</i> , 2008, 18, 1000-1006.	2.1	29
93	⁹⁹ MTC-Sestamibi as sole technique in selection of primary hyperparathyroidism patients for unilateral neck exploration. <i>Surgery</i> , 2008, 144, 454-459.	1.9	27
94	Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. <i>Human Reproduction</i> , 2008, 23, 1594-1601.	0.9	39
95	Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2008, 159, 225-232.	3.7	18
96	Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2007, 22, 3197-3203.	0.9	128
97	Obesity Is the Major Determinant of the Abnormalities in Blood Pressure Found in Young Women with the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2141-2148.	3.6	65
98	Increased Body Iron Stores of Obese Women With Polycystic Ovary Syndrome Are a Consequence of Insulin Resistance and Hyperinsulinism and Are Not a Result of Reduced Menstrual Losses. <i>Diabetes Care</i> , 2007, 30, 2309-2313.	8.6	77
99	Comparison of Ethinyl-Estradiol Plus Cyproterone Acetate Versus Metformin Effects on Classic Metabolic Cardiovascular Risk Factors in Women with the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2453-2461.	3.6	92
100	Cost of management of invasive growth hormone-secreting macroadenoma. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 541-545.	3.3	21
101	Fibrosis quística, bocio e hipertiroidismo. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2007, 54, 125-128.	0.8	2
102	The decrease in serum IL-18 levels after bariatric surgery in morbidly obese women is a time-dependent event. <i>Obesity Surgery</i> , 2007, 17, 1199-1208.	2.1	17
103	The decrease in serum IL-18 levels after bariatric surgery in morbidly obese women is a time-dependent event. <i>Obesity Surgery</i> , 2007, 17, 1199-1208.	2.1	3
104	The PON1 ^{108C/T} polymorphism, and not the polycystic ovary syndrome, is an important determinant of reduced serum paraoxonase activity in premenopausal women. <i>Human Reproduction</i> , 2006, 21, 3157-3161.	0.9	16
105	Genomic variants in polycystic ovary syndrome. <i>Clinica Chimica Acta</i> , 2006, 366, 14-26.	1.1	43
106	Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. <i>Human Reproduction</i> , 2006, 21, 2257-2265.	0.9	167
107	Mutations in the Hereditary Hemochromatosis Gene Are Not Associated With the Increased Body Iron Stores Observed in Overweight and Obese Women With Polycystic Ovary Syndrome. <i>Diabetes Care</i> , 2006, 29, 2556-2556.	8.6	14
108	A Study of the Hexose-6-Phosphate Dehydrogenase Gene R453Q and 11 ^β -Hydroxysteroid Dehydrogenase Type 1 Gene 83557insA Polymorphisms in the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4157-4162.	3.6	63

#	ARTICLE	IF	CITATIONS
109	Body Iron Stores Are Increased in Overweight and Obese Women With Polycystic Ovary Syndrome. <i>Diabetes Care</i> , 2005, 28, 2042-2044.	8.6	43
110	The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome. <i>Endocrine Reviews</i> , 2005, 26, 251-282.	20.1	359
111	Calcificación metastásica de adenoma mixto productor de prolactina y hormona de crecimiento.. <i>Medicina Clínica</i> , 2004, 123, 400-400.	0.6	0
112	Incidence of Air Travel-Related Pulmonary Embolism at the Madrid-Barajas Airport. <i>Archives of Internal Medicine</i> , 2003, 163, 2766.	3.8	120
113	Hiponatremia grave asociada al uso de fluoxetina en el anciano. <i>Revista Clinica Espanola</i> , 2002, 202, 246.	0.6	1
114	Oral glucose tolerance test vs fasting plasma glucose determination for the assessment of glucose metabolism disturbances in women with Polycystic Ovary Syndrome. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
115	Diagnosis and management of severe hyperandrogenism in the context of tumoral suspicion: case-series report from a tertiary hospital. <i>Endocrine Abstracts</i> , 0, , .	0.0	0